Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galmed Pharmaceutica (NQ: GLMD )

4.998 -0.822 (-14.12%)
Streaming Delayed Price Updated: 3:45 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Galmed Pharmaceutica

< Previous 1 2 3 4 Next >
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 49 companies reached new 52-week lows. 
Via Benzinga
Galmed Pharmaceuticals: Q2 Earnings Insights
  Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
Via Benzinga
Recap: Galmed Pharmaceuticals Q4 Earnings
Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q4 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Galmed Pharmaceuticals: Q1 Earnings Insights
Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00. Shares of Galmed Pharmaceuticals are trading down... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Upgrades 
Via Benzinga
Galmed Pharmaceuticals's Earnings Outlook
Galmed Pharmaceuticals (NASDAQ:GLMD) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Galmed... 
Via Benzinga
Galmed Pharmaceuticals Q4 2021 Earnings Conference Call On May 2, 2022 At 08:30 AM ET
Galmed Pharmaceuticals (NASDAQ:GLMD) will host a conference call at 08:30 AM ET on May 2, 2022, to discuss Q4 2021 earnings results. 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Earnings Scheduled For May 2, 2022
Companies Reporting Before The Bell • New Gold (AMEX:NGD) is estimated to report quarterly earnings at $0.03 per share on revenue of $212.42 million. 
Via Benzinga
25 Stocks Moving in Friday's Pre-Market Session
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading... 
Via Benzinga
Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of... 
Via Benzinga
Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of... 
Via Benzinga
26 Stocks Moving in Monday's Pre-Market Session
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed... 
Via Benzinga
Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled... 
Via Benzinga
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares jumped 64.8% to $8.04 on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) surged 60.3% to $5.93 after the company... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application... 
Via Benzinga
Exposures Product Safety
64 Biggest Movers From Friday
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.